Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Anxiety

Research spanning pharmacological, contemplative, and psychedelic-assisted approaches to pathological anxiety.

State of the evidence

Synthesized

Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.

Research indicates that both mindfulness-based interventions (MBIs) and psychedelic-assisted therapies (e.g., psilocybin, LSD, ayahuasca, DMT, ketamine) can reduce anxiety across various populations, with psychedelic studies often showing rapid and sustained effects in patients with life-threatening illness or treatment-resistant conditions. However, evidence is limited by small sample sizes, open-label designs, and a lack of long-term follow-up in many studies, particularly for MBIs in student populations and for psychedelics in broader clinical groups.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

Mindfulness meditation programs had moderate evidence of improved anxiety at 8 weeks (effect size 0.38) and at 3-6 months (effect size 0.22).

meta-analysis of RCTs Sample size: 3515

High-dose psilocybin produced large decreases in anxiety, sustained at 6 months, with about 80% of participants showing clinically significant decreases.

RCT (double-blind, crossover) Sample size: 51

Mindfulness meditation training significantly reduced anxiety and panic symptoms, maintained at 3-month follow-up.

observational (pre-post with follow-up) Sample size: 22

Single-dose psilocybin produced immediate, substantial, and sustained improvements in anxiety at 7 weeks and 6.5 months, with 60–80% of participants maintaining clinically significant reductions.

RCT (double-blind, placebo-controlled, crossover) Sample size: 29

Psilocybin (0.2 mg/kg) significantly reduced trait anxiety at 1 and 3 months post-treatment, with no serious adverse events.

RCT (double-blind, placebo-controlled, crossover) Sample size: 12

LSD-assisted psychotherapy significantly reduced trait and state anxiety at 2 months (effect sizes 1.1 and 1.2), sustained for 12 months.

RCT (double-blind, active placebo-controlled pilot) Sample size: 12

Mindfulness-based interventions are effective for improving anxiety, but many reviews indicate low quality of included studies.

review

MBIs showed significant positive effects on anxiety/stress (d = 0.18) compared to active controls, but effects were small.

meta-analysis of RCTs Sample size: 3666

Psilocybin dose-dependently induced anxiety/panic in a small proportion of subjects at high doses, but most described the experience as pleasurable and non-threatening.

pooled analysis of experimental studies Sample size: 110

Ayahuasca showed fast-acting anxiolytic effects in patients with a depressive disorder.

preliminary report (open-label)

Psilocybin-assisted therapy produced a 59% reduction in anxiety (GAD-7) at Week 3, sustained through 12 months, but effects were no longer significant after accounting for depressive symptom improvement.

open-label trial Sample size: 15

MBIs show promise in reducing anxiety in students, but limitations include geographic bias, homogeneous samples, and lack of long-term follow-up.

systematic review

Inhaled DMT reduced state anxiety up to 1 day after administration in all volunteers, and patients showed sustained improvements in life satisfaction and quality of life up to 12 months.

open-label clinical trials Sample size: 41

Ketamine reduced anxiety in TR-PTSD patients (correlated with EEG alpha changes) but not in TR-MDD patients; effects varied by diagnosis.

observational (within-subject, counterbalanced) Sample size: 22

Ketamine-assisted psychotherapy sessions with higher mystical experience scores were associated with greater therapeutic gains in anxiety.

case study Sample size: 1

Points of agreement

  • Both MBIs and psychedelic-assisted therapies show anxiety-reducing effects across multiple populations.
  • Psychedelic studies consistently report rapid onset and sustained benefits (months to a year) in patients with life-threatening illness or treatment-resistant conditions.
  • Mindfulness-based interventions show small but significant effects on anxiety in meta-analyses, including in children/adolescents and students.

Conflicts

  • Psychedelic studies report large effect sizes, while MBI meta-analyses show small effect sizes (d = 0.18–0.38).
  • Ketamine's anxiolytic effects appear diagnosis-specific (effective in PTSD but not MDD in one study), whereas psilocybin and LSD show more consistent effects across anxiety-related conditions.
  • One study found that psilocybin's anxiety improvements were no longer significant after controlling for depression changes, suggesting possible overlap in symptom measurement.

Gaps

  • Most psychedelic studies have small sample sizes (12–51) and lack long-term follow-up beyond 12 months.
  • MBI research in students and children lacks diversity in samples and long-term sustainability data.
  • Few studies directly compare different psychedelics or MBIs head-to-head for anxiety.
  • Mechanisms linking acute subjective effects (e.g., mystical experiences) to sustained anxiety reduction are not fully understood.
  • Durability of effects beyond 12 months is largely unstudied for both MBIs and psychedelics.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Latest monthly recap: June 2026 →

4,209 articles · 1,694 from the last two years · 2,362,219 participants across 2,157 studies reporting sample size

Common study designs

review 633 systematic review 249 observational cohort 159 randomized controlled trial 562 theoretical or philosophical paper 198

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

Journal of Affective Disorders November 1, 2026 Carlton M Kelly, Mathieu Fradet, Catherine Bostian et al.

A single 25-mg dose of psilocybin with psychological support was associated with sustained improvements in anxiety, quality of life, functioning, and PTSD symptoms in 15 veterans with treatment-resistant depression. Anxiety scores dropped 59% from baseline at three weeks and remained lower through 12 months. Quality of life increased 24% and functional impairment decreased 46% at three weeks, though these effects were no longer statistically significant after accounting for concurrent improvements in depression. PTSD symptom reductions were observed at all timepoints. Acute subjective experiences did not correlate with treatment response. The study is limited by its small sample and open-label design.

Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) on depression and anxiety in older adults: A systematic review and meta-analysis.

Journal of behavior therapy and experimental psychiatry September 1, 2026 Jieping Ding, Zafar Mehnaz Ali, Ateya Megahed Ibrahim et al.

Mindfulness-Based Cognitive Therapy (MBCT) may reduce depressive symptoms in adults aged 60 years and older compared with control conditions. A meta-analysis of three randomized controlled trials involving 178 participants found that MBCT was associated with significantly lower depressive symptom severity (pooled effect size Hedges g = -0.92, 95% confidence interval -1.30 to -0.55, with no heterogeneity). Evidence for anxiety and quality-of-life outcomes was limited and could not be pooled, and no trials reported relapse or recurrence. The authors note the evidence base remains small and heterogeneous, calling for larger, methodologically rigorous trials with standardized outcomes and longer follow-up.

Esketamine alleviates trigeminal neuralgia and anxiety-like behaviors in mice by inhibiting RIPK1/RIPK3/MLKL-mediated necroptosis.

Brain Research Bulletin August 1, 2026 Rui Dong, Jiaxin Liu, Yumei Shen et al.

In a mouse model of trigeminal neuralgia (TN) that also shows anxiety-like behavior, esketamine (ES) given for five days dose-dependently reduced pain and anxiety. TN caused damage to neurons in the hippocampus and increased levels of the necroptosis pathway proteins RIPK1, RIPK3, and MLKL. ES treatment reversed these changes, protecting neurons and restoring dendritic spines. Adding a necroptosis activator blocked ES's effects, confirming that ES works by inhibiting the RIPK1/RIPK3/MLKL pathway. The findings highlight necroptosis as a key mechanism linking TN pain to emotional disorders and suggest ES could be repurposed as a treatment for both pain and anxiety in TN.

Yoga, Meditation, and Breathing Techniques on Stress and Anxiety : A Systematic Literature Review and a Proposal for an Integrated Neurosomatic Mental Health Model

Zenodo (CERN European Organization for Nuclear Research) July 19, 2026 Gönültaş Gökben

Yoga, meditation, and breathing techniques may reduce stress, anxiety, and psychological distress while improving emotional regulation and psychological resilience. A systematic review of studies from PubMed, Scopus, Web of Science, PsycINFO, Google Scholar, TR Dizin, and DergiPark, following PRISMA 2020 guidelines, found evidence that these mind–body practices work through interoceptive awareness, autonomic nervous system regulation, vagal activation, and neuroplasticity. Based on the findings, the authors propose an Integrated Neurosomatic Mental Health Model that links neurosomatic awareness, interoception, autonomic regulation, neurocognitive restructuring, emotional regulation, resilience, and well-being. The model suggests interconnected neurobiological, psychological, and physiological pathways for how these practices affect mental health.

Effectiveness of Mindfulness Therapy on Anxiety among Elderly Residents at Panti Sosial Tresna Werdha Natar

Genius Journal July 15, 2026 Anisa Fitri, Sujiah Sujiah, Miranti Dea Dora

Mindfulness therapy significantly reduced anxiety among older adults in a residential care home. In a study of 38 residents with anxiety, the mean anxiety score dropped from 21.05 before the intervention to 16.39 afterward, a statistically significant reduction. The therapy offers a non-pharmacological option for managing anxiety in this population, who often face loneliness, fear of death, and feelings of abandonment after relocation.

Mindfulness Development via Biofeedback for Anxiety in Hospitalized Patients: A Randomized Controlled Trial

Brain Sciences July 15, 2026 Anastasia V. Kotelnikova, Vera M. Ruzinova, Maria G. Kiseleva et al.

Adding biofeedback to anxiety disorder treatment reduces anxiety and improves mindfulness more than medication alone. Inpatients with anxiety disorders were randomly assigned to biofeedback for enhancing mindfulness, medication therapy (escitalopram 10 mg/day), or combined therapy. After 10 days of treatment and at one-month follow-up, the biofeedback and combined groups showed significantly greater reductions in anxiety (measured by the Hamilton Anxiety Rating Scale) and increases in mindfulness (measured by the Five Facet Mindfulness Questionnaire) compared to the medication-only group, which showed a decrease in mindfulness. The biofeedback and combined groups did not differ significantly from each other. These findings suggest biofeedback may be a promising component of comprehensive anxiety therapy.

Combined Liuzijue and mindful breathing promote greater sustained relaxation than mindful breathing alone in university students with anxiety symptoms

Frontiers in Psychology July 13, 2026 Wen-Ming Liang, Inga Griškova-bulanova, Jing Xiao et al.

Combining Liuzijue breathing, a traditional Chinese practice of controlled abdominal movements and low-pitched vocalization, with mindful breathing produced more sustained relaxation in anxious male university students than mindful breathing alone. In a randomized crossover trial of 24 male participants aged 21 ± 2 with anxiety symptoms, the combination sequence (5 minutes Liuzijue breathing followed by 10 minutes mindful breathing) led to greater continued reductions in heart rate and greater progressive increases in heart rate variability compared to 15 minutes of mindful breathing alone. Participants also reported significantly higher concentration during mindful breathing after Liuzijue breathing. During Liuzijue breathing, respiration rate was lower and peripheral oxygen saturation was higher, with end-tidal carbon dioxide lower during minutes 2–5. These physiological changes may explain the enhanced relaxation.

Effectiveness of an 8-Week Meditation Intervention on Stress, Anxiety, and Sleep Quality in Older Adults: A Randomised Controlled Trial

International Journal For Multidisciplinary Research July 11, 2026 Pushpendra Yaduvanshi, Barkha Sahu, Tanay Bhardwaj

An 8-week structured meditation program involving guided sessions of 30–45 minutes produced clinically meaningful improvements in perceived stress and sleep quality among 58 community-dwelling older adults aged 60 years or older with mild-to-moderate stress, anxiety, or sleep disturbance. Both meditation protocols led to very large reductions in perceived stress (44–47%) and sleep disturbance (40–47%), with no significant difference between the two protocols for these outcomes. Only one of the two protocols significantly reduced anxiety (by 46.5%), while the other's anxiety reduction was not statistically significant. The findings suggest that meditation strategies should be selected according to the predominant symptom profile, particularly when anxiety is a primary concern.

Breathwork for Sexual Anxiety

July 10, 2026 Lohani Noor

Sexual anxiety, whether from trauma, performance shame, or arousal dysregulation, hinders intimacy, pleasure, and connection. Breathwork, as a foundational somatic practice, provides an accessible method to regulate the autonomic nervous system, reduce anxiety, and anchor present-moment awareness—core elements for healthy sexual engagement. In psychosexual therapy, structured breathing fosters embodiment, somatic safety, and trust, helping clients reconnect with sensation and desire.

Efficacy comparison of mindfulness-based cognitive therapy and routine support on anxiety and sleep quality in peritoneal dialysis patients

World Journal of Psychiatry July 8, 2026 Yu-Peng Liu, Chen-Chen Shen, Jing Li et al.

In patients undergoing peritoneal dialysis, an 8-week mindfulness-based cognitive therapy program was associated with greater improvements in anxiety, sleep quality, depressive symptoms, and quality of life compared with routine psychological support. At both treatment end and 3-month follow-up, the mindfulness group showed significantly reduced anxiety symptoms, lower new-onset anxiety, and better sleep quality, including improved sleep onset latency, total sleep time, fewer sleep disorders, and less daytime dysfunction. Depressive symptoms and both mental and physical quality of life also improved more with mindfulness-based cognitive therapy than with routine support.

Clinical trials

All Anxiety trials →